ALL21_BLOTA
ID ALL21_BLOTA Reviewed; 129 AA.
AC A7IZE9; A7IZF1; A7IZF2; A7IZF3; A7IZF5;
DT 16-JAN-2019, integrated into UniProtKB/Swiss-Prot.
DT 11-SEP-2007, sequence version 1.
DT 25-MAY-2022, entry version 36.
DE RecName: Full=Mite allergen Blo t 21 {ECO:0000305};
DE AltName: Full=Mite group 21 allergen Blo t 21 {ECO:0000303|PubMed:22887997};
DE AltName: Allergen=Blo t 21 {ECO:0000303|PubMed:17445876, ECO:0000303|PubMed:22887997, ECO:0000303|PubMed:23445659};
DE Flags: Precursor;
OS Blomia tropicalis (Mite).
OC Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Chelicerata; Arachnida; Acari;
OC Acariformes; Sarcoptiformes; Astigmata; Glycyphagoidea; Echimyopodidae;
OC Blomia.
OX NCBI_TaxID=40697 {ECO:0000312|EMBL:ABH06344.1};
RN [1] {ECO:0000312|EMBL:ABH06344.1, ECO:0000312|EMBL:ABH06346.1, ECO:0000312|EMBL:ABH06347.1, ECO:0000312|EMBL:ABH06348.1, ECO:0000312|EMBL:ABH06350.1}
RP NUCLEOTIDE SEQUENCE [MRNA], NUCLEOTIDE SEQUENCE [GENOMIC DNA], SUBUNIT,
RP TISSUE SPECIFICITY, ALLERGEN, AND CIRCULAR DICHROISM ANALYSIS.
RX PubMed=17445876; DOI=10.1016/j.jaci.2007.02.032;
RA Gao Y.F., Wang D.Y., Ong T.C., Tay S.L., Yap K.H., Chew F.T.;
RT "Identification and characterization of a novel allergen from Blomia
RT tropicalis: Blo t 21.";
RL J. Allergy Clin. Immunol. 120:105-112(2007).
RN [2]
RP ALLERGEN.
RX PubMed=23445659; DOI=10.1186/1471-2172-14-11;
RA dos Anjos Carvalho K., de Melo-Neto O.P., Magalhaes F.B., Ponte J.C.,
RA Felipe F.A., dos Santos M.C., dos Santos Lima G., Cruz A.A., Pinheiro C.S.,
RA Pontes-de-Carvalho L.C., Alcantara-Neves N.M.;
RT "Blomia tropicalis Blo t 5 and Blo t 21 recombinant allergens might confer
RT higher specificity to serodiagnostic assays than whole mite extract.";
RL BMC Immunol. 14:11-11(2013).
RN [3] {ECO:0007744|PDB:2LM9}
RP STRUCTURE BY NMR OF 34-129, ALLERGEN, MUTAGENESIS OF ARG-39; GLU-42;
RP LYS-45; GLU-53; GLU-58; LYS-59; GLU-65; LYS-66; GLU-77; ARG-84; GLU-90;
RP ASP-95; ASP-97; GLU-100; GLU-105; ASP-112 AND LYS-123, AND CIRCULAR
RP DICHROISM ANALYSIS.
RX PubMed=22887997; DOI=10.1074/jbc.m112.348730;
RA Tan K.W., Ong T.C., Gao Y.F., Tiong Y.S., Wong K.N., Chew F.T., Mok Y.K.;
RT "NMR structure and IgE epitopes of Blo t 21, a major dust mite allergen
RT from Blomia tropicalis.";
RL J. Biol. Chem. 287:34776-34785(2012).
CC -!- SUBUNIT: May exist as homodimer and homotrimer.
CC {ECO:0000269|PubMed:17445876}.
CC -!- TISSUE SPECIFICITY: Midgut and hindgut contents as well as fecal
CC pellets (at protein level). {ECO:0000269|PubMed:17445876}.
CC -!- ALLERGEN: Causes an allergic reaction in human. Binds to IgE. Common
CC symptoms of mite allergy are bronchial asthma, allergic rhinitis and
CC conjunctivitis. {ECO:0000269|PubMed:17445876,
CC ECO:0000269|PubMed:22887997, ECO:0000269|PubMed:23445659}.
CC -!- SIMILARITY: Belongs to the mite group 5 allergen family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AY800348; AAX34047.1; -; mRNA.
DR EMBL; DQ788677; ABH06344.1; -; Genomic_DNA.
DR EMBL; DQ788678; ABH06345.1; -; Genomic_DNA.
DR EMBL; DQ788679; ABH06346.1; -; Genomic_DNA.
DR EMBL; DQ788680; ABH06347.1; -; Genomic_DNA.
DR EMBL; DQ788681; ABH06348.1; -; Genomic_DNA.
DR EMBL; DQ788682; ABH06349.1; -; Genomic_DNA.
DR EMBL; DQ788683; ABH06350.1; -; Genomic_DNA.
DR PDB; 2LM9; NMR; -; A=34-129.
DR PDBsum; 2LM9; -.
DR AlphaFoldDB; A7IZE9; -.
DR SMR; A7IZE9; -.
DR Allergome; 3568; Blo t 21.
DR Allergome; 3569; Blo t 21.0101.
DR GO; GO:0019863; F:IgE binding; IMP:UniProtKB.
DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR Gene3D; 1.20.58.970; -; 1.
DR InterPro; IPR020306; Mite_allergen_group-5/21.
DR InterPro; IPR038455; Mite_allergen_group-5/21_sf.
DR Pfam; PF11642; Blo-t-5; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Allergen; Signal.
FT SIGNAL 1..16
FT /evidence="ECO:0000255"
FT CHAIN 17..129
FT /note="Mite allergen Blo t 21"
FT /evidence="ECO:0000255"
FT /id="PRO_5010958292"
FT MUTAGEN 39
FT /note="R->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 42
FT /note="E->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 45
FT /note="K->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 53
FT /note="E->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 58
FT /note="E->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 59
FT /note="K->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 65
FT /note="E->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 66
FT /note="K->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 77
FT /note="E->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 84
FT /note="R->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 90
FT /note="E->A: Over 20% reduction in IgE-binding. Further
FT reduction in IgE-binding; when associated with A-95, A-100
FT or A-105. Most significant reduction in IgE-binding; when
FT associated with A-95 and A-105 or with A-95; A-105 and A-
FT 112."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 95
FT /note="D->A: Over 20% reduction in IgE-binding. Further
FT reduction in IgE-binding; when associated with A-90 or A-
FT 105. Most significant reduction in IgE-binding; when
FT associated with A-90 and A-105, with A-105 and A-112 or
FT with A-90; A-105 and A-112."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 97
FT /note="D->A: No effect in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 100
FT /note="E->A: Over 20% reduction in IgE-binding. Further
FT reduction of IgE-binding; when associated with A-90."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 105
FT /note="E->A: Over 20% reduction in IgE-binding. Further
FT reduction in IgE-binding; when associated with A-90, A-95
FT or A-112. Most significant reduction in IgE-binding; when
FT associated with A-90 and A-95, with A-95 and A-112 or with
FT A-90; A-95 and A-112."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 112
FT /note="D->A: Over 20% reduction in IgE-binding. Further
FT reduction in IgE-binding; when associated with A-105, with
FT A-95 and A-105 or with A-90; A-95 and A-105."
FT /evidence="ECO:0000269|PubMed:22887997"
FT MUTAGEN 123
FT /note="K->A: Over 20% reduction in IgE-binding."
FT /evidence="ECO:0000269|PubMed:22887997"
FT CONFLICT 33
FT /note="V -> I (in Ref. 1; ABH06348/ABH06349)"
FT /evidence="ECO:0000305"
FT CONFLICT 35
FT /note="T -> A (in Ref. 1; ABH06347)"
FT /evidence="ECO:0000305"
FT CONFLICT 59
FT /note="K -> E (in Ref. 1; ABH06350)"
FT /evidence="ECO:0000305"
FT CONFLICT 69
FT /note="L -> P (in Ref. 1; ABH06346)"
FT /evidence="ECO:0000305"
FT HELIX 35..60
FT /evidence="ECO:0007829|PDB:2LM9"
FT HELIX 65..90
FT /evidence="ECO:0007829|PDB:2LM9"
FT HELIX 98..128
FT /evidence="ECO:0007829|PDB:2LM9"
SQ SEQUENCE 129 AA; 14843 MW; E7D26CC3B29F85C7 CRC64;
MKFIIALAAL IAVACALPVS NDNFRHEFDH MIVNTATQRF HEIEKFLLHI THEVDDLEKT
GNKDEKARLL RELTVSEAFI EGSRGYFQRE LKRTDLDLLE KFNFEAALAT GDLLLKDLKA
LQKRVQDSE
